#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Results and Discussion
1-1	0-2	3.	object[1]	new[1]	_	_
1-2	3-10	Results	object[1]	new[1]	_	_
1-3	11-14	and	_	_	_	_
1-4	15-25	Discussion	abstract	new	_	_

#Text=During the drug design process , to assess the potential druggability of a compound as a new starting point , some initial rules like drug-likeness ( as defined by Lipinski and colleagues in 1997 ) , lead-likeness ( as defined by Oprea ) and known drug space , are usually applied .
2-1	26-32	During	_	_	_	_
2-2	33-36	the	event[5]	new[5]	_	_
2-3	37-41	drug	substance|event[5]	new|new[5]	coref	2-46
2-4	42-48	design	abstract|event[5]	new|new[5]	_	_
2-5	49-56	process	event[5]	new[5]	_	_
2-6	57-58	,	_	_	_	_
2-7	59-61	to	_	_	_	_
2-8	62-68	assess	_	_	_	_
2-9	69-72	the	abstract[6]	new[6]	_	_
2-10	73-82	potential	abstract[6]	new[6]	_	_
2-11	83-95	druggability	abstract[6]	new[6]	_	_
2-12	96-98	of	abstract[6]	new[6]	_	_
2-13	99-100	a	abstract[6]|abstract[7]	new[6]|new[7]	coref	3-8[0_7]
2-14	101-109	compound	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-15	110-112	as	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-16	113-114	a	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-17	115-118	new	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-18	119-127	starting	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-19	128-133	point	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-20	134-135	,	_	_	_	_
2-21	136-140	some	abstract[8]	new[8]	coref	3-4[18_8]
2-22	141-148	initial	abstract[8]	new[8]	_	_
2-23	149-154	rules	abstract[8]	new[8]	_	_
2-24	155-159	like	abstract[8]	new[8]	_	_
2-25	160-173	drug-likeness	abstract[8]|abstract	new[8]|new	_	_
2-26	174-175	(	_	_	_	_
2-27	176-178	as	_	_	_	_
2-28	179-186	defined	_	_	_	_
2-29	187-189	by	_	_	_	_
2-30	190-198	Lipinski	person	new	_	_
2-31	199-202	and	_	_	_	_
2-32	203-213	colleagues	person	new	_	_
2-33	214-216	in	_	_	_	_
2-34	217-221	1997	time	new	_	_
2-35	222-223	)	_	_	_	_
2-36	224-225	,	_	_	_	_
2-37	226-239	lead-likeness	substance	new	_	_
2-38	240-241	(	_	_	_	_
2-39	242-244	as	_	_	_	_
2-40	245-252	defined	_	_	_	_
2-41	253-255	by	_	_	_	_
2-42	256-261	Oprea	person	new	_	_
2-43	262-263	)	_	_	_	_
2-44	264-267	and	_	_	_	_
2-45	268-273	known	place[16]	new[16]	coref	4-19[36_16]
2-46	274-278	drug	substance|place[16]	giv|new[16]	_	_
2-47	279-284	space	place[16]	new[16]	_	_
2-48	285-286	,	_	_	_	_
2-49	287-290	are	_	_	_	_
2-50	291-298	usually	_	_	_	_
2-51	299-306	applied	_	_	_	_
2-52	307-308	.	_	_	_	_

#Text=In general , the rules to characterise/filter compound collections are based upon physicochemical parameters , e. g. , logP , logS , MW , TPSA , MR , RotN , HBA and HBD , among others .
3-1	309-311	In	_	_	_	_
3-2	312-319	general	person	new	_	_
3-3	320-321	,	_	_	_	_
3-4	322-325	the	abstract[18]	giv[18]	coref	6-15[53_18]
3-5	326-331	rules	abstract[18]	giv[18]	_	_
3-6	332-334	to	abstract[18]	giv[18]	_	_
3-7	335-354	characterise/filter	abstract[18]|abstract[20]	giv[18]|new[20]	_	_
3-8	355-363	compound	abstract[18]|abstract|abstract[20]	giv[18]|giv|new[20]	coref	22-27
3-9	364-375	collections	abstract[18]|abstract[20]	giv[18]|new[20]	_	_
3-10	376-379	are	_	_	_	_
3-11	380-385	based	_	_	_	_
3-12	386-390	upon	_	_	_	_
3-13	391-406	physicochemical	abstract[21]	new[21]	_	_
3-14	407-417	parameters	abstract[21]	new[21]	_	_
3-15	418-419	,	_	_	_	_
3-16	420-422	e.	_	_	_	_
3-17	423-425	g.	_	_	_	_
3-18	426-427	,	_	_	_	_
3-19	428-432	logP	abstract	new	_	_
3-20	433-434	,	_	_	_	_
3-21	435-439	logS	abstract	new	_	_
3-22	440-441	,	_	_	_	_
3-23	442-444	MW	abstract	new	_	_
3-24	445-446	,	_	_	_	_
3-25	447-451	TPSA	abstract	new	_	_
3-26	452-453	,	_	_	_	_
3-27	454-456	MR	abstract	new	_	_
3-28	457-458	,	_	_	_	_
3-29	459-463	RotN	abstract	new	_	_
3-30	464-465	,	_	_	_	_
3-31	466-469	HBA	abstract	new	_	_
3-32	470-473	and	_	_	_	_
3-33	474-477	HBD	abstract	new	_	_
3-34	478-479	,	_	_	_	_
3-35	480-485	among	_	_	_	_
3-36	486-492	others	_	_	_	_
3-37	493-494	.	_	_	_	_

#Text=As a result , it would be interesting to assess how proteasome inhibitors are positioned with respect to the typically expected “ drug-like ” chemical space .
4-1	495-497	As	_	_	_	_
4-2	498-499	a	abstract[30]	new[30]	_	_
4-3	500-506	result	abstract[30]	new[30]	_	_
4-4	507-508	,	_	_	_	_
4-5	509-511	it	abstract	new	cata	4-5[0_32]
4-6	512-517	would	_	_	_	_
4-7	518-520	be	_	_	_	_
4-8	521-532	interesting	_	_	_	_
4-9	533-535	to	abstract[32]	new[32]	_	_
4-10	536-542	assess	abstract[32]	new[32]	_	_
4-11	543-546	how	abstract[32]	new[32]	_	_
4-12	547-557	proteasome	abstract[32]|abstract[33]	new[32]|new[33]	coref	5-15[0_33]
4-13	558-568	inhibitors	abstract[32]|abstract[33]	new[32]|new[33]	_	_
4-14	569-572	are	abstract[32]	new[32]	_	_
4-15	573-583	positioned	abstract[32]	new[32]	_	_
4-16	584-588	with	_	_	_	_
4-17	589-596	respect	abstract[34]	new[34]	_	_
4-18	597-599	to	abstract[34]	new[34]	_	_
4-19	600-603	the	abstract[34]|place[36]	new[34]|giv[36]	coref	6-6[0_36]
4-20	604-613	typically	abstract[34]|place[36]	new[34]|giv[36]	_	_
4-21	614-622	expected	abstract[34]|place[36]	new[34]|giv[36]	_	_
4-22	623-624	“	abstract[34]|place[36]	new[34]|giv[36]	_	_
4-23	625-634	drug-like	abstract[34]|substance|place[36]	new[34]|new|giv[36]	_	_
4-24	635-636	”	abstract[34]|place[36]	new[34]|giv[36]	_	_
4-25	637-645	chemical	abstract[34]|place[36]	new[34]|giv[36]	_	_
4-26	646-651	space	abstract[34]|place[36]	new[34]|giv[36]	_	_
4-27	652-653	.	_	_	_	_

#Text=To do so , we performed a comprehensive analysis of the 680 small-molecules proteasome inhibitors dataset spanning a large range of activity ( 0.08 nM < IC50 ≤ 150,000 nM ) .
5-1	654-656	To	_	_	_	_
5-2	657-659	do	_	_	_	_
5-3	660-662	so	_	_	_	_
5-4	663-664	,	_	_	_	_
5-5	665-667	we	person	acc	ana	11-3
5-6	668-677	performed	_	_	_	_
5-7	678-679	a	abstract[38]	new[38]	coref	12-3[92_38]
5-8	680-693	comprehensive	abstract[38]	new[38]	_	_
5-9	694-702	analysis	abstract[38]	new[38]	_	_
5-10	703-705	of	abstract[38]	new[38]	_	_
5-11	706-709	the	abstract[38]|abstract[41]	new[38]|new[41]	coref	8-1[68_41]
5-12	710-713	680	abstract[38]|abstract[41]	new[38]|new[41]	_	_
5-13	714-729	small-molecules	abstract[38]|abstract|abstract[41]	new[38]|new|new[41]	_	_
5-14	730-740	proteasome	abstract[38]|abstract[41]	new[38]|new[41]	_	_
5-15	741-751	inhibitors	abstract[38]|abstract|abstract[41]	new[38]|giv|new[41]	coref	10-11[87_0]
5-16	752-759	dataset	abstract[38]|abstract[41]	new[38]|new[41]	_	_
5-17	760-768	spanning	_	_	_	_
5-18	769-770	a	abstract[42]	new[42]	_	_
5-19	771-776	large	abstract[42]	new[42]	_	_
5-20	777-782	range	abstract[42]	new[42]	_	_
5-21	783-785	of	abstract[42]	new[42]	_	_
5-22	786-794	activity	abstract[42]|abstract	new[42]|new	ana	6-1
5-23	795-796	(	_	_	_	_
5-24	797-801	0.08	quantity[44]	new[44]	_	_
5-25	802-804	nM	quantity[44]	new[44]	_	_
5-26	805-806	<	_	_	_	_
5-27	807-811	IC50	quantity	new	_	_
5-28	812-813	≤	_	_	_	_
5-29	814-821	150,000	quantity[46]	new[46]	_	_
5-30	822-824	nM	quantity[46]	new[46]	_	_
5-31	825-826	)	_	_	_	_
5-32	827-828	.	_	_	_	_

#Text=This entailed looking at chemical space distribution , scaffold similarity and the extraction of chemical rules with machine learning , using either direct structural information ( scaffolds and Morgan fingerprints ) or being based on 21 general molecular ( QuaSAR ) descriptors .
6-1	829-833	This	abstract	giv	coref	7-17[67_0]
6-2	834-842	entailed	_	_	_	_
6-3	843-850	looking	_	_	_	_
6-4	851-853	at	_	_	_	_
6-5	854-862	chemical	abstract[49]	new[49]	coref	10-3[83_49]
6-6	863-868	space	place|abstract[49]	giv|new[49]	coref	10-4
6-7	869-881	distribution	abstract[49]	new[49]	_	_
6-8	882-883	,	_	_	_	_
6-9	884-892	scaffold	quantity|abstract[51]	new|new[51]	coref|coref|coref|coref	10-8|10-7[85_51]|10-8|10-7[85_51]
6-10	893-903	similarity	abstract[51]	new[51]	_	_
6-11	904-907	and	_	_	_	_
6-12	908-911	the	abstract[52]	new[52]	_	_
6-13	912-922	extraction	abstract[52]	new[52]	_	_
6-14	923-925	of	abstract[52]	new[52]	_	_
6-15	926-934	chemical	abstract[52]|abstract[53]	new[52]|giv[53]	_	_
6-16	935-940	rules	abstract[52]|abstract[53]	new[52]|giv[53]	_	_
6-17	941-945	with	abstract[52]|abstract[53]	new[52]|giv[53]	_	_
6-18	946-953	machine	abstract[52]|abstract[53]|abstract[54]	new[52]|giv[53]|new[54]	_	_
6-19	954-962	learning	abstract[52]|abstract[53]|abstract[54]	new[52]|giv[53]|new[54]	_	_
6-20	963-964	,	_	_	_	_
6-21	965-970	using	_	_	_	_
6-22	971-977	either	abstract[55]	new[55]	coref	12-23[97_55]
6-23	978-984	direct	abstract[55]	new[55]	_	_
6-24	985-995	structural	abstract[55]	new[55]	_	_
6-25	996-1007	information	abstract[55]	new[55]	_	_
6-26	1008-1009	(	_	_	_	_
6-27	1010-1019	scaffolds	object|object[57]	new|new[57]	coref|coref|coref|coref	24-10[175_0]|28-24[200_57]|24-10[175_0]|28-24[200_57]
6-28	1020-1023	and	object[57]	new[57]	_	_
6-29	1024-1030	Morgan	object[57]|person|object[59]	new[57]|new|new[59]	_	_
6-30	1031-1043	fingerprints	object[57]|object[59]	new[57]|new[59]	_	_
6-31	1044-1045	)	_	_	_	_
6-32	1046-1048	or	_	_	_	_
6-33	1049-1054	being	_	_	_	_
6-34	1055-1060	based	_	_	_	_
6-35	1061-1063	on	_	_	_	_
6-36	1064-1066	21	quantity[60]|abstract[62]	new[60]|new[62]	coref|coref	12-16[96_62]|12-16[96_62]
6-37	1067-1074	general	quantity[60]|abstract[62]	new[60]|new[62]	_	_
6-38	1075-1084	molecular	quantity[60]|abstract[62]	new[60]|new[62]	_	_
6-39	1085-1086	(	abstract[62]	new[62]	_	_
6-40	1087-1093	QuaSAR	abstract|abstract[62]	new|new[62]	_	_
6-41	1094-1095	)	abstract[62]	new[62]	_	_
6-42	1096-1107	descriptors	abstract[62]	new[62]	_	_
6-43	1108-1109	.	_	_	_	_

#Text=This set of analyses was ultimately employed to produce meaningful chemical patterns that are correlated with proteasome inhibitory activity .
7-1	1110-1114	This	abstract[63]	new[63]	_	_
7-2	1115-1118	set	abstract[63]	new[63]	_	_
7-3	1119-1121	of	abstract[63]	new[63]	_	_
7-4	1122-1130	analyses	abstract[63]|abstract	new[63]|new	_	_
7-5	1131-1134	was	_	_	_	_
7-6	1135-1145	ultimately	_	_	_	_
7-7	1146-1154	employed	_	_	_	_
7-8	1155-1157	to	_	_	_	_
7-9	1158-1165	produce	_	_	_	_
7-10	1166-1176	meaningful	abstract[65]	new[65]	_	_
7-11	1177-1185	chemical	abstract[65]	new[65]	_	_
7-12	1186-1194	patterns	abstract[65]	new[65]	_	_
7-13	1195-1199	that	_	_	_	_
7-14	1200-1203	are	_	_	_	_
7-15	1204-1214	correlated	_	_	_	_
7-16	1215-1219	with	_	_	_	_
7-17	1220-1230	proteasome	abstract[67]	giv[67]	coref	8-7[0_67]
7-18	1231-1241	inhibitory	abstract|abstract[67]	new|giv[67]	_	_
7-19	1242-1250	activity	abstract[67]	giv[67]	_	_
7-20	1251-1252	.	_	_	_	_

#Text=The dataset comprises only human proteasome activity data for the CT-L catalytic site , as this is the only site with the largest number of compounds , and is divided into four classes .
8-1	1253-1256	The	abstract[68]	giv[68]	coref	24-22[179_68]
8-2	1257-1264	dataset	abstract[68]	giv[68]	_	_
8-3	1265-1274	comprises	_	_	_	_
8-4	1275-1279	only	abstract[70]	new[70]	coref	9-1[78_70]
8-5	1280-1285	human	abstract[70]	new[70]	_	_
8-6	1286-1296	proteasome	abstract[70]	new[70]	_	_
8-7	1297-1305	activity	abstract|abstract[70]	giv|new[70]	coref	16-11
8-8	1306-1310	data	abstract[70]	new[70]	_	_
8-9	1311-1314	for	abstract[70]	new[70]	_	_
8-10	1315-1318	the	abstract[70]|place[72]	new[70]|new[72]	ana	8-16[0_72]
8-11	1319-1323	CT-L	abstract[70]|abstract|place[72]	new[70]|new|new[72]	_	_
8-12	1324-1333	catalytic	abstract[70]|place[72]	new[70]|new[72]	_	_
8-13	1334-1338	site	abstract[70]|place[72]	new[70]|new[72]	_	_
8-14	1339-1340	,	_	_	_	_
8-15	1341-1343	as	_	_	_	_
8-16	1344-1348	this	place	giv	coref	8-18[74_0]
8-17	1349-1351	is	_	_	_	_
8-18	1352-1355	the	place[74]	giv[74]	_	_
8-19	1356-1360	only	place[74]	giv[74]	_	_
8-20	1361-1365	site	place[74]	giv[74]	_	_
8-21	1366-1370	with	place[74]	giv[74]	_	_
8-22	1371-1374	the	place[74]|quantity[75]	giv[74]|new[75]	_	_
8-23	1375-1382	largest	place[74]|quantity[75]	giv[74]|new[75]	_	_
8-24	1383-1389	number	place[74]|quantity[75]	giv[74]|new[75]	_	_
8-25	1390-1392	of	place[74]|quantity[75]	giv[74]|new[75]	_	_
8-26	1393-1402	compounds	place[74]|quantity[75]|substance	giv[74]|new[75]|new	coref	16-18[115_0]
8-27	1403-1404	,	_	_	_	_
8-28	1405-1408	and	_	_	_	_
8-29	1409-1411	is	_	_	_	_
8-30	1412-1419	divided	_	_	_	_
8-31	1420-1424	into	_	_	_	_
8-32	1425-1429	four	person[77]	new[77]	coref	16-9[114_77]
8-33	1430-1437	classes	person[77]	new[77]	_	_
8-34	1438-1439	.	_	_	_	_

#Text=Full data are available in Table S1 .
9-1	1440-1444	Full	abstract[78]	giv[78]	_	_
9-2	1445-1449	data	abstract[78]	giv[78]	_	_
9-3	1450-1453	are	_	_	_	_
9-4	1454-1463	available	_	_	_	_
9-5	1464-1466	in	_	_	_	_
9-6	1467-1472	Table	abstract|object[80]	new|new[80]	coref|coref|coref|coref	12-27|12-27[99_80]|12-27|12-27[99_80]
9-7	1473-1475	S1	object[80]	new[80]	_	_
9-8	1476-1477	.	_	_	_	_

#Text=Analysis of chemical space distribution and the scaffold similarity of proteasome inhibitors .
10-1	1478-1486	Analysis	abstract[81]	new[81]	_	_
10-2	1487-1489	of	abstract[81]	new[81]	_	_
10-3	1490-1498	chemical	abstract[81]|abstract[83]	new[81]|giv[83]	coref	11-5[91_83]
10-4	1499-1504	space	abstract[81]|place|abstract[83]	new[81]|giv|giv[83]	coref	11-10
10-5	1505-1517	distribution	abstract[81]|abstract[83]	new[81]|giv[83]	_	_
10-6	1518-1521	and	abstract[81]	new[81]	_	_
10-7	1522-1525	the	abstract[81]|abstract[85]	new[81]|giv[85]	coref	22-11[159_85]
10-8	1526-1534	scaffold	abstract[81]|quantity|abstract[85]	new[81]|giv|giv[85]	_	_
10-9	1535-1545	similarity	abstract[81]|abstract[85]	new[81]|giv[85]	_	_
10-10	1546-1548	of	abstract[81]|abstract[85]	new[81]|giv[85]	_	_
10-11	1549-1559	proteasome	abstract[81]|abstract[85]|abstract|object[87]	new[81]|giv[85]|new|giv[87]	coref|coref	11-5[89_87]|11-5[89_87]
10-12	1560-1570	inhibitors	abstract[81]|abstract[85]|object[87]	new[81]|giv[85]|giv[87]	_	_
10-13	1571-1572	.	_	_	_	_

#Text=First , we analyzed human proteasome inhibitors ’ chemical space distribution .
11-1	1573-1578	First	_	_	_	_
11-2	1579-1580	,	_	_	_	_
11-3	1581-1583	we	person	giv	ana	21-34
11-4	1584-1592	analyzed	_	_	_	_
11-5	1593-1598	human	abstract[89]|abstract[91]	giv[89]|giv[91]	coref|coref	20-33[147_89]|20-33[147_89]
11-6	1599-1609	proteasome	abstract[89]|abstract[91]	giv[89]|giv[91]	_	_
11-7	1610-1620	inhibitors	abstract[89]|abstract[91]	giv[89]|giv[91]	_	_
11-8	1621-1622	’	abstract[89]|abstract[91]	giv[89]|giv[91]	_	_
11-9	1623-1631	chemical	abstract[91]	giv[91]	_	_
11-10	1632-1637	space	place|abstract[91]	giv|giv[91]	coref	12-6[93_0]
11-11	1638-1650	distribution	abstract[91]	giv[91]	_	_
11-12	1651-1652	.	_	_	_	_

#Text=To address this analysis , chemical space was defined by the t-SNE calculation applied to the 21 calculated molecular descriptors listed in the Supplementary Information ( Table S1 ) .
12-1	1653-1655	To	_	_	_	_
12-2	1656-1663	address	_	_	_	_
12-3	1664-1668	this	abstract[92]	giv[92]	_	_
12-4	1669-1677	analysis	abstract[92]	giv[92]	_	_
12-5	1678-1679	,	_	_	_	_
12-6	1680-1688	chemical	place[93]	giv[93]	coref	13-35[109_93]
12-7	1689-1694	space	place[93]	giv[93]	_	_
12-8	1695-1698	was	_	_	_	_
12-9	1699-1706	defined	_	_	_	_
12-10	1707-1709	by	_	_	_	_
12-11	1710-1713	the	abstract[95]	new[95]	_	_
12-12	1714-1719	t-SNE	abstract|abstract[95]	new|new[95]	_	_
12-13	1720-1731	calculation	abstract[95]	new[95]	_	_
12-14	1732-1739	applied	_	_	_	_
12-15	1740-1742	to	_	_	_	_
12-16	1743-1746	the	abstract[96]	giv[96]	coref	21-31[154_96]
12-17	1747-1749	21	abstract[96]	giv[96]	_	_
12-18	1750-1760	calculated	abstract[96]	giv[96]	_	_
12-19	1761-1770	molecular	abstract[96]	giv[96]	_	_
12-20	1771-1782	descriptors	abstract[96]	giv[96]	_	_
12-21	1783-1789	listed	_	_	_	_
12-22	1790-1792	in	_	_	_	_
12-23	1793-1796	the	abstract[97]	giv[97]	_	_
12-24	1797-1810	Supplementary	abstract[97]	giv[97]	_	_
12-25	1811-1822	Information	abstract[97]	giv[97]	_	_
12-26	1823-1824	(	_	_	_	_
12-27	1825-1830	Table	abstract|object[99]	giv|giv[99]	_	_
12-28	1831-1833	S1	object[99]	giv[99]	_	_
12-29	1834-1835	)	_	_	_	_
12-30	1836-1837	.	_	_	_	_

#Text=The proximity in a t-SNE plot is relative in nature , and the distance between points simply represents relative proximity ( i. e. , it is not a direct scaling from real distances in the 21 dimensional space ) .
13-1	1838-1841	The	abstract[100]	new[100]	coref	13-19[105_100]
13-2	1842-1851	proximity	abstract[100]	new[100]	_	_
13-3	1852-1854	in	abstract[100]	new[100]	_	_
13-4	1855-1856	a	abstract[100]|abstract[101]	new[100]|new[101]	coref	16-44[123_101]
13-5	1857-1862	t-SNE	abstract[100]|abstract[101]	new[100]|new[101]	_	_
13-6	1863-1867	plot	abstract[100]|abstract[101]	new[100]|new[101]	_	_
13-7	1868-1870	is	_	_	_	_
13-8	1871-1879	relative	_	_	_	_
13-9	1880-1882	in	_	_	_	_
13-10	1883-1889	nature	abstract	new	_	_
13-11	1890-1891	,	_	_	_	_
13-12	1892-1895	and	_	_	_	_
13-13	1896-1899	the	object[103]	new[103]	_	_
13-14	1900-1908	distance	object[103]	new[103]	_	_
13-15	1909-1916	between	object[103]	new[103]	_	_
13-16	1917-1923	points	object[103]|object	new[103]|new	_	_
13-17	1924-1930	simply	_	_	_	_
13-18	1931-1941	represents	_	_	_	_
13-19	1942-1950	relative	abstract[105]	giv[105]	ana	13-25[0_105]
13-20	1951-1960	proximity	abstract[105]	giv[105]	_	_
13-21	1961-1962	(	_	_	_	_
13-22	1963-1965	i.	_	_	_	_
13-23	1966-1968	e.	_	_	_	_
13-24	1969-1970	,	_	_	_	_
13-25	1971-1973	it	abstract	giv	_	_
13-26	1974-1976	is	_	_	_	_
13-27	1977-1980	not	_	_	_	_
13-28	1981-1982	a	abstract[107]	new[107]	_	_
13-29	1983-1989	direct	abstract[107]	new[107]	_	_
13-30	1990-1997	scaling	abstract[107]	new[107]	_	_
13-31	1998-2002	from	abstract[107]	new[107]	_	_
13-32	2003-2007	real	abstract[107]|abstract[108]	new[107]|new[108]	_	_
13-33	2008-2017	distances	abstract[107]|abstract[108]	new[107]|new[108]	_	_
13-34	2018-2020	in	abstract[107]|abstract[108]	new[107]|new[108]	_	_
13-35	2021-2024	the	abstract[107]|abstract[108]|place[109]	new[107]|new[108]|giv[109]	coref	21-21[152_109]
13-36	2025-2027	21	abstract[107]|abstract[108]|place[109]	new[107]|new[108]|giv[109]	_	_
13-37	2028-2039	dimensional	abstract[107]|abstract[108]|place[109]	new[107]|new[108]|giv[109]	_	_
13-38	2040-2045	space	abstract[107]|abstract[108]|place[109]	new[107]|new[108]|giv[109]	_	_
13-39	2046-2047	)	_	_	_	_
13-40	2048-2049	.	_	_	_	_

#Text=In
14-1	2050-2052	In	_	_	_	_

#Text=Figure 4
15-1	2053-2059	Figure	abstract[110]	new[110]	coref	17-1[131_110]
15-2	2060-2061	4	abstract[110]	new[110]	_	_

#Text=( left ) the difference of distribution of the four activity classes is easily perceptible , with the most active compounds ( class A , purple ) having close to half of its compounds ( ~47 % ) in the top-right quadrant of the plot , while the least active compounds ( class D , orange ) are mainly concentrated in the bottom-left quadrant ( ~58 % of class D compounds ) , as quantified in
16-1	2062-2063	(	_	_	_	_
16-2	2064-2068	left	_	_	_	_
16-3	2069-2070	)	_	_	_	_
16-4	2071-2074	the	abstract[111]	new[111]	_	_
16-5	2075-2085	difference	abstract[111]	new[111]	_	_
16-6	2086-2088	of	abstract[111]	new[111]	_	_
16-7	2089-2101	distribution	abstract[111]|abstract[112]	new[111]|new[112]	coref	19-12[137_112]
16-8	2102-2104	of	abstract[111]|abstract[112]	new[111]|new[112]	_	_
16-9	2105-2108	the	abstract[111]|abstract[112]|person[114]	new[111]|new[112]|giv[114]	coref	19-1[0_114]
16-10	2109-2113	four	abstract[111]|abstract[112]|person[114]	new[111]|new[112]|giv[114]	_	_
16-11	2114-2122	activity	abstract[111]|abstract[112]|abstract|person[114]	new[111]|new[112]|giv|giv[114]	coref	27-8
16-12	2123-2130	classes	abstract[111]|abstract[112]|person[114]	new[111]|new[112]|giv[114]	_	_
16-13	2131-2133	is	_	_	_	_
16-14	2134-2140	easily	_	_	_	_
16-15	2141-2152	perceptible	_	_	_	_
16-16	2153-2154	,	_	_	_	_
16-17	2155-2159	with	_	_	_	_
16-18	2160-2163	the	substance[115]	giv[115]	coref	16-33[120_115]
16-19	2164-2168	most	substance[115]	giv[115]	_	_
16-20	2169-2175	active	substance[115]	giv[115]	_	_
16-21	2176-2185	compounds	substance[115]	giv[115]	_	_
16-22	2186-2187	(	_	_	_	_
16-23	2188-2193	class	abstract	new	appos	16-53[125_0]
16-24	2194-2195	A	abstract[117]	new[117]	ana	16-33[0_117]
16-25	2196-2197	,	abstract[117]	new[117]	_	_
16-26	2198-2204	purple	abstract[117]	new[117]	_	_
16-27	2205-2206	)	_	_	_	_
16-28	2207-2213	having	_	_	_	_
16-29	2214-2219	close	_	_	_	_
16-30	2220-2222	to	_	_	_	_
16-31	2223-2227	half	quantity[118]	new[118]	_	_
16-32	2228-2230	of	quantity[118]	new[118]	_	_
16-33	2231-2234	its	quantity[118]|abstract|substance[120]	new[118]|giv|giv[120]	coref|coref	16-48[124_120]|16-48[124_120]
16-34	2235-2244	compounds	quantity[118]|substance[120]	new[118]|giv[120]	_	_
16-35	2245-2246	(	quantity[118]	new[118]	_	_
16-36	2247-2250	~47	quantity[118]|quantity[121]	new[118]|new[121]	coref	16-66[127_121]
16-37	2251-2252	%	quantity[118]|quantity[121]	new[118]|new[121]	_	_
16-38	2253-2254	)	quantity[118]	new[118]	_	_
16-39	2255-2257	in	quantity[118]	new[118]	_	_
16-40	2258-2261	the	quantity[118]|place[122]	new[118]|new[122]	coref	16-62[126_122]
16-41	2262-2271	top-right	quantity[118]|place[122]	new[118]|new[122]	_	_
16-42	2272-2280	quadrant	quantity[118]|place[122]	new[118]|new[122]	_	_
16-43	2281-2283	of	quantity[118]|place[122]	new[118]|new[122]	_	_
16-44	2284-2287	the	quantity[118]|place[122]|abstract[123]	new[118]|new[122]|giv[123]	_	_
16-45	2288-2292	plot	quantity[118]|place[122]|abstract[123]	new[118]|new[122]|giv[123]	_	_
16-46	2293-2294	,	_	_	_	_
16-47	2295-2300	while	_	_	_	_
16-48	2301-2304	the	substance[124]	giv[124]	coref	16-69[130_124]
16-49	2305-2310	least	substance[124]	giv[124]	_	_
16-50	2311-2317	active	substance[124]	giv[124]	_	_
16-51	2318-2327	compounds	substance[124]	giv[124]	_	_
16-52	2328-2329	(	_	_	_	_
16-53	2330-2335	class	abstract[125]	giv[125]	coref	20-4[142_125]
16-54	2336-2337	D	abstract[125]	giv[125]	_	_
16-55	2338-2339	,	_	_	_	_
16-56	2340-2346	orange	_	_	_	_
16-57	2347-2348	)	_	_	_	_
16-58	2349-2352	are	_	_	_	_
16-59	2353-2359	mainly	_	_	_	_
16-60	2360-2372	concentrated	_	_	_	_
16-61	2373-2375	in	_	_	_	_
16-62	2376-2379	the	place[126]	giv[126]	_	_
16-63	2380-2391	bottom-left	place[126]	giv[126]	_	_
16-64	2392-2400	quadrant	place[126]	giv[126]	_	_
16-65	2401-2402	(	_	_	_	_
16-66	2403-2406	~58	quantity[127]	giv[127]	_	_
16-67	2407-2408	%	quantity[127]	giv[127]	_	_
16-68	2409-2411	of	quantity[127]	giv[127]	_	_
16-69	2412-2417	class	quantity[127]|person|substance[130]	giv[127]|new|giv[130]	coref|coref	24-42[0_130]|24-42[0_130]
16-70	2418-2419	D	quantity[127]|person|substance[130]	giv[127]|new|giv[130]	coref	28-40
16-71	2420-2429	compounds	quantity[127]|substance[130]	giv[127]|giv[130]	_	_
16-72	2430-2431	)	_	_	_	_
16-73	2432-2433	,	_	_	_	_
16-74	2434-2436	as	_	_	_	_
16-75	2437-2447	quantified	_	_	_	_
16-76	2448-2450	in	_	_	_	_

#Text=Figure 4
17-1	2451-2457	Figure	abstract[131]	giv[131]	_	_
17-2	2458-2459	4	abstract[131]	giv[131]	_	_

#Text=( right ) .
18-1	2460-2461	(	_	_	_	_
18-2	2462-2467	right	_	_	_	_
18-3	2468-2469	)	_	_	_	_
18-4	2470-2471	.	_	_	_	_

#Text=Classes B ( blue ) and C ( green ) have a more disperse distribution , but show some higher density areas close to the bottom-left corner .
19-1	2472-2479	Classes	person|place[133]	giv|new[133]	coref|coref|coref|coref	20-14[143_0]|28-5[0_133]|20-14[143_0]|28-5[0_133]
19-2	2480-2481	B	place[133]	new[133]	_	_
19-3	2482-2483	(	place[133]	new[133]	_	_
19-4	2484-2488	blue	place[133]	new[133]	_	_
19-5	2489-2490	)	place[133]	new[133]	_	_
19-6	2491-2494	and	place[133]	new[133]	_	_
19-7	2495-2496	C	place[133]|person	new[133]|new	_	_
19-8	2497-2498	(	_	_	_	_
19-9	2499-2504	green	abstract	new	_	_
19-10	2505-2506	)	_	_	_	_
19-11	2507-2511	have	_	_	_	_
19-12	2512-2513	a	abstract[137]	giv[137]	ana	20-1[0_137]
19-13	2514-2518	more	object[136]|abstract[137]	new[136]|giv[137]	_	_
19-14	2519-2527	disperse	object[136]|abstract[137]	new[136]|giv[137]	_	_
19-15	2528-2540	distribution	abstract[137]	giv[137]	_	_
19-16	2541-2542	,	_	_	_	_
19-17	2543-2546	but	_	_	_	_
19-18	2547-2551	show	_	_	_	_
19-19	2552-2556	some	place[139]	new[139]	_	_
19-20	2557-2563	higher	place[139]	new[139]	_	_
19-21	2564-2571	density	abstract|place[139]	new|new[139]	_	_
19-22	2572-2577	areas	place[139]	new[139]	_	_
19-23	2578-2583	close	place[139]	new[139]	_	_
19-24	2584-2586	to	_	_	_	_
19-25	2587-2590	the	place[140]	new[140]	_	_
19-26	2591-2602	bottom-left	place[140]	new[140]	_	_
19-27	2603-2609	corner	place[140]	new[140]	_	_
19-28	2610-2611	.	_	_	_	_

#Text=This indicates that class D , for example , is fundamentally different to the remaining classes from a structural and physicochemical level , and therefore supports the existence of a SAR in the proteasome inhibitors developed in the last 20 years .
20-1	2612-2616	This	abstract	giv	coref	23-17[171_0]
20-2	2617-2626	indicates	_	_	_	_
20-3	2627-2631	that	_	_	_	_
20-4	2632-2637	class	abstract[142]	giv[142]	coref	21-9[150_142]
20-5	2638-2639	D	abstract[142]	giv[142]	_	_
20-6	2640-2641	,	_	_	_	_
20-7	2642-2645	for	_	_	_	_
20-8	2646-2653	example	_	_	_	_
20-9	2654-2655	,	_	_	_	_
20-10	2656-2658	is	_	_	_	_
20-11	2659-2672	fundamentally	_	_	_	_
20-12	2673-2682	different	_	_	_	_
20-13	2683-2685	to	_	_	_	_
20-14	2686-2689	the	person[143]	giv[143]	coref	23-15[169_143]
20-15	2690-2699	remaining	person[143]	giv[143]	_	_
20-16	2700-2707	classes	person[143]	giv[143]	_	_
20-17	2708-2712	from	person[143]	giv[143]	_	_
20-18	2713-2714	a	person[143]|abstract[144]	giv[143]|new[144]	_	_
20-19	2715-2725	structural	person[143]|abstract[144]	giv[143]|new[144]	_	_
20-20	2726-2729	and	person[143]|abstract[144]	giv[143]|new[144]	_	_
20-21	2730-2745	physicochemical	person[143]|abstract[144]	giv[143]|new[144]	_	_
20-22	2746-2751	level	person[143]|abstract[144]	giv[143]|new[144]	_	_
20-23	2752-2753	,	_	_	_	_
20-24	2754-2757	and	_	_	_	_
20-25	2758-2767	therefore	_	_	_	_
20-26	2768-2776	supports	_	_	_	_
20-27	2777-2780	the	abstract[145]	new[145]	_	_
20-28	2781-2790	existence	abstract[145]	new[145]	_	_
20-29	2791-2793	of	abstract[145]	new[145]	_	_
20-30	2794-2795	a	abstract[145]|place[146]	new[145]|new[146]	_	_
20-31	2796-2799	SAR	abstract[145]|place[146]	new[145]|new[146]	_	_
20-32	2800-2802	in	abstract[145]|place[146]	new[145]|new[146]	_	_
20-33	2803-2806	the	abstract[145]|place[146]|abstract[147]	new[145]|new[146]|giv[147]	coref	22-14[160_147]
20-34	2807-2817	proteasome	abstract[145]|place[146]|abstract[147]	new[145]|new[146]|giv[147]	_	_
20-35	2818-2828	inhibitors	abstract[145]|place[146]|abstract[147]	new[145]|new[146]|giv[147]	_	_
20-36	2829-2838	developed	_	_	_	_
20-37	2839-2841	in	_	_	_	_
20-38	2842-2845	the	time[148]	new[148]	_	_
20-39	2846-2850	last	time[148]	new[148]	_	_
20-40	2851-2853	20	time[148]	new[148]	_	_
20-41	2854-2859	years	time[148]	new[148]	_	_
20-42	2860-2861	.	_	_	_	_

#Text=Additionally , no particular cluster was formed with a single class , which means there is no particular location in chemical space ( at least one that is defined by the descriptors that we considered ) which is reserved to one single class .
21-1	2862-2874	Additionally	_	_	_	_
21-2	2875-2876	,	_	_	_	_
21-3	2877-2879	no	object[149]	new[149]	_	_
21-4	2880-2890	particular	object[149]	new[149]	_	_
21-5	2891-2898	cluster	object[149]	new[149]	_	_
21-6	2899-2902	was	_	_	_	_
21-7	2903-2909	formed	_	_	_	_
21-8	2910-2914	with	_	_	_	_
21-9	2915-2916	a	abstract[150]	giv[150]	coref	21-41[156_150]
21-10	2917-2923	single	abstract[150]	giv[150]	_	_
21-11	2924-2929	class	abstract[150]	giv[150]	_	_
21-12	2930-2931	,	_	_	_	_
21-13	2932-2937	which	_	_	_	_
21-14	2938-2943	means	_	_	_	_
21-15	2944-2949	there	_	_	_	_
21-16	2950-2952	is	_	_	_	_
21-17	2953-2955	no	place[151]	new[151]	_	_
21-18	2956-2966	particular	place[151]	new[151]	_	_
21-19	2967-2975	location	place[151]	new[151]	_	_
21-20	2976-2978	in	place[151]	new[151]	_	_
21-21	2979-2987	chemical	place[151]|place[152]	new[151]|giv[152]	coref	23-19[0_152]
21-22	2988-2993	space	place[151]|place[152]	new[151]|giv[152]	_	_
21-23	2994-2995	(	place[151]|place[152]	new[151]|giv[152]	_	_
21-24	2996-2998	at	place[151]|place[152]|quantity[153]	new[151]|giv[152]|new[153]	_	_
21-25	2999-3004	least	place[151]|place[152]|quantity[153]	new[151]|giv[152]|new[153]	_	_
21-26	3005-3008	one	place[151]|place[152]|quantity[153]	new[151]|giv[152]|new[153]	_	_
21-27	3009-3013	that	_	_	_	_
21-28	3014-3016	is	_	_	_	_
21-29	3017-3024	defined	_	_	_	_
21-30	3025-3027	by	_	_	_	_
21-31	3028-3031	the	abstract[154]	giv[154]	_	_
21-32	3032-3043	descriptors	abstract[154]	giv[154]	_	_
21-33	3044-3048	that	_	_	_	_
21-34	3049-3051	we	person	giv	ana	23-3
21-35	3052-3062	considered	_	_	_	_
21-36	3063-3064	)	_	_	_	_
21-37	3065-3070	which	_	_	_	_
21-38	3071-3073	is	_	_	_	_
21-39	3074-3082	reserved	_	_	_	_
21-40	3083-3085	to	_	_	_	_
21-41	3086-3089	one	abstract[156]	giv[156]	coref	24-13[176_156]
21-42	3090-3096	single	abstract[156]	giv[156]	_	_
21-43	3097-3102	class	abstract[156]	giv[156]	_	_
21-44	3103-3104	.	_	_	_	_

#Text=This observation indicates that carrying out compound selection biased for physicochemical similarity to known inhibitors might be a good initial filter to enrich the set of compound candidates with active hits .
22-1	3105-3109	This	abstract[157]	new[157]	coref	29-40[216_157]
22-2	3110-3121	observation	abstract[157]	new[157]	_	_
22-3	3122-3131	indicates	_	_	_	_
22-4	3132-3136	that	_	_	_	_
22-5	3137-3145	carrying	_	_	_	_
22-6	3146-3149	out	_	_	_	_
22-7	3150-3158	compound	abstract[158]	new[158]	_	_
22-8	3159-3168	selection	abstract[158]	new[158]	_	_
22-9	3169-3175	biased	_	_	_	_
22-10	3176-3179	for	_	_	_	_
22-11	3180-3195	physicochemical	abstract[159]	giv[159]	coref	24-7[173_159]
22-12	3196-3206	similarity	abstract[159]	giv[159]	_	_
22-13	3207-3209	to	abstract[159]	giv[159]	_	_
22-14	3210-3215	known	abstract[159]|abstract[160]	giv[159]|giv[160]	_	_
22-15	3216-3226	inhibitors	abstract[159]|abstract[160]	giv[159]|giv[160]	_	_
22-16	3227-3232	might	_	_	_	_
22-17	3233-3235	be	_	_	_	_
22-18	3236-3237	a	object[161]	new[161]	_	_
22-19	3238-3242	good	object[161]	new[161]	_	_
22-20	3243-3250	initial	object[161]	new[161]	_	_
22-21	3251-3257	filter	object[161]	new[161]	_	_
22-22	3258-3260	to	_	_	_	_
22-23	3261-3267	enrich	_	_	_	_
22-24	3268-3271	the	abstract[162]	new[162]	_	_
22-25	3272-3275	set	abstract[162]	new[162]	_	_
22-26	3276-3278	of	abstract[162]	new[162]	_	_
22-27	3279-3287	compound	abstract[162]|abstract|person[164]	new[162]|giv|new[164]	_	_
22-28	3288-3298	candidates	abstract[162]|person[164]	new[162]|new[164]	_	_
22-29	3299-3303	with	abstract[162]|person[164]	new[162]|new[164]	_	_
22-30	3304-3310	active	abstract[162]|person[164]|abstract[165]	new[162]|new[164]|new[165]	_	_
22-31	3311-3315	hits	abstract[162]|person[164]|abstract[165]	new[162]|new[164]|new[165]	_	_
22-32	3316-3317	.	_	_	_	_

#Text=Next , we wanted to investigate what characteristics are responsible for the differences between classes in the chemical space distribution .
23-1	3318-3322	Next	_	_	_	_
23-2	3323-3324	,	_	_	_	_
23-3	3325-3327	we	person	giv	ana	24-16
23-4	3328-3334	wanted	_	_	_	_
23-5	3335-3337	to	_	_	_	_
23-6	3338-3349	investigate	_	_	_	_
23-7	3350-3354	what	_	_	_	_
23-8	3355-3370	characteristics	abstract	new	_	_
23-9	3371-3374	are	_	_	_	_
23-10	3375-3386	responsible	_	_	_	_
23-11	3387-3390	for	_	_	_	_
23-12	3391-3394	the	abstract[168]	new[168]	_	_
23-13	3395-3406	differences	abstract[168]	new[168]	_	_
23-14	3407-3414	between	abstract[168]	new[168]	_	_
23-15	3415-3422	classes	abstract[168]|person[169]	new[168]|giv[169]	coref	24-34[181_169]
23-16	3423-3425	in	abstract[168]|person[169]	new[168]|giv[169]	_	_
23-17	3426-3429	the	abstract[168]|person[169]|abstract[171]	new[168]|giv[169]|giv[171]	coref	28-17[197_171]
23-18	3430-3438	chemical	abstract[168]|person[169]|abstract[171]	new[168]|giv[169]|giv[171]	_	_
23-19	3439-3444	space	abstract[168]|person[169]|place|abstract[171]	new[168]|giv[169]|giv|giv[171]	coref	29-42
23-20	3445-3457	distribution	abstract[168]|person[169]|abstract[171]	new[168]|giv[169]|giv[171]	_	_
23-21	3458-3459	.	_	_	_	_

#Text=Upon applying the Tc to characterize the similarity between Murcko scaffolds within each class , we observed a high diversity in the dataset , not just within each class , but also between the different classes , with most pairs of compounds showing a Tc below 0.5 that represents a considerable dissimilarity (
24-1	3460-3464	Upon	_	_	_	_
24-2	3465-3473	applying	_	_	_	_
24-3	3474-3477	the	abstract[172]	new[172]	coref	24-44[184_172]
24-4	3478-3480	Tc	abstract[172]	new[172]	_	_
24-5	3481-3483	to	_	_	_	_
24-6	3484-3496	characterize	_	_	_	_
24-7	3497-3500	the	abstract[173]	giv[173]	coref	27-10[0_173]
24-8	3501-3511	similarity	abstract[173]	giv[173]	_	_
24-9	3512-3519	between	abstract[173]	giv[173]	_	_
24-10	3520-3526	Murcko	abstract[173]|abstract|object[175]	giv[173]|new|giv[175]	coref|coref	28-1[192_175]|28-1[192_175]
24-11	3527-3536	scaffolds	abstract[173]|object[175]	giv[173]|giv[175]	_	_
24-12	3537-3543	within	abstract[173]|object[175]	giv[173]|giv[175]	_	_
24-13	3544-3548	each	abstract[173]|object[175]|abstract[176]	giv[173]|giv[175]|giv[176]	coref	24-26[180_176]
24-14	3549-3554	class	abstract[173]|object[175]|abstract[176]	giv[173]|giv[175]|giv[176]	_	_
24-15	3555-3556	,	_	_	_	_
24-16	3557-3559	we	person	giv	_	_
24-17	3560-3568	observed	_	_	_	_
24-18	3569-3570	a	abstract[178]	new[178]	_	_
24-19	3571-3575	high	abstract[178]	new[178]	_	_
24-20	3576-3585	diversity	abstract[178]	new[178]	_	_
24-21	3586-3588	in	abstract[178]	new[178]	_	_
24-22	3589-3592	the	abstract[178]|abstract[179]	new[178]|giv[179]	_	_
24-23	3593-3600	dataset	abstract[178]|abstract[179]	new[178]|giv[179]	_	_
24-24	3601-3602	,	abstract[178]|abstract[179]	new[178]|giv[179]	_	_
24-25	3603-3606	not	abstract[178]|abstract[179]	new[178]|giv[179]	_	_
24-26	3607-3611	just	abstract[178]|abstract[179]|abstract[180]	new[178]|giv[179]|giv[180]	coref	28-4[0_180]
24-27	3612-3618	within	abstract[178]|abstract[179]|abstract[180]	new[178]|giv[179]|giv[180]	_	_
24-28	3619-3623	each	abstract[178]|abstract[179]|abstract[180]	new[178]|giv[179]|giv[180]	_	_
24-29	3624-3629	class	abstract[178]|abstract[179]|abstract[180]	new[178]|giv[179]|giv[180]	_	_
24-30	3630-3631	,	_	_	_	_
24-31	3632-3635	but	_	_	_	_
24-32	3636-3640	also	_	_	_	_
24-33	3641-3648	between	_	_	_	_
24-34	3649-3652	the	person[181]	giv[181]	coref	28-27[201_181]
24-35	3653-3662	different	person[181]	giv[181]	_	_
24-36	3663-3670	classes	person[181]	giv[181]	_	_
24-37	3671-3672	,	person[181]	giv[181]	_	_
24-38	3673-3677	with	person[181]	giv[181]	_	_
24-39	3678-3682	most	person[181]|plant[182]	giv[181]|new[182]	_	_
24-40	3683-3688	pairs	person[181]|plant[182]	giv[181]|new[182]	_	_
24-41	3689-3691	of	person[181]|plant[182]	giv[181]|new[182]	_	_
24-42	3692-3701	compounds	person[181]|plant[182]|substance	giv[181]|new[182]|giv	coref	28-35[204_0]
24-43	3702-3709	showing	_	_	_	_
24-44	3710-3711	a	abstract[184]	giv[184]	_	_
24-45	3712-3714	Tc	abstract[184]	giv[184]	_	_
24-46	3715-3720	below	quantity[185]	new[185]	_	_
24-47	3721-3724	0.5	quantity[185]	new[185]	_	_
24-48	3725-3729	that	_	_	_	_
24-49	3730-3740	represents	_	_	_	_
24-50	3741-3742	a	abstract[186]	new[186]	_	_
24-51	3743-3755	considerable	abstract[186]	new[186]	_	_
24-52	3756-3769	dissimilarity	abstract[186]	new[186]	_	_
24-53	3770-3771	(	_	_	_	_

#Text=Figure 5
25-1	3772-3778	Figure	abstract[187]	new[187]	_	_
25-2	3779-3780	5	abstract[187]	new[187]	_	_

#Text=) .
26-1	3781-3782	)	_	_	_	_
26-2	3783-3784	.	_	_	_	_

#Text=Nonetheless a clear trend of correlation between activity and similarity is observed .
27-1	3785-3796	Nonetheless	_	_	_	_
27-2	3797-3798	a	abstract[188]	new[188]	_	_
27-3	3799-3804	clear	abstract[188]	new[188]	_	_
27-4	3805-3810	trend	abstract[188]	new[188]	_	_
27-5	3811-3813	of	abstract[188]	new[188]	_	_
27-6	3814-3825	correlation	abstract[188]|abstract[189]	new[188]|new[189]	_	_
27-7	3826-3833	between	abstract[188]|abstract[189]	new[188]|new[189]	_	_
27-8	3834-3842	activity	abstract[188]|abstract[189]|abstract	new[188]|new[189]|giv	coref	28-36
27-9	3843-3846	and	abstract[188]|abstract[189]	new[188]|new[189]	_	_
27-10	3847-3857	similarity	abstract[188]|abstract[189]|abstract	new[188]|new[189]|giv	_	_
27-11	3858-3860	is	_	_	_	_
27-12	3861-3869	observed	_	_	_	_
27-13	3870-3871	.	_	_	_	_

#Text=The scaffolds of class B differ negligibly from class A , however , class C shows a two-peak distribution which suggests it contains scaffolds similar to both classes A/B , as well as with lower activity compounds ( class D ) .
28-1	3872-3875	The	object[192]	giv[192]	coref	28-24[199_192]
28-2	3876-3885	scaffolds	object[192]	giv[192]	_	_
28-3	3886-3888	of	object[192]	giv[192]	_	_
28-4	3889-3894	class	object[192]|abstract	giv[192]|giv	coref	28-9
28-5	3895-3896	B	place	giv	_	_
28-6	3897-3903	differ	_	_	_	_
28-7	3904-3914	negligibly	_	_	_	_
28-8	3915-3919	from	_	_	_	_
28-9	3920-3925	class	abstract	giv	coref	28-10[196_0]
28-10	3926-3927	A	abstract[196]	giv[196]	coref	28-39[205_196]
28-11	3928-3929	,	abstract[196]	giv[196]	_	_
28-12	3930-3937	however	abstract[196]	giv[196]	_	_
28-13	3938-3939	,	abstract[196]	giv[196]	_	_
28-14	3940-3945	class	abstract[196]	giv[196]	_	_
28-15	3946-3947	C	abstract[196]	giv[196]	_	_
28-16	3948-3953	shows	_	_	_	_
28-17	3954-3955	a	abstract[197]	giv[197]	ana	28-22[0_197]
28-18	3956-3964	two-peak	abstract[197]	giv[197]	_	_
28-19	3965-3977	distribution	abstract[197]	giv[197]	_	_
28-20	3978-3983	which	_	_	_	_
28-21	3984-3992	suggests	_	_	_	_
28-22	3993-3995	it	abstract	giv	_	_
28-23	3996-4004	contains	_	_	_	_
28-24	4005-4014	scaffolds	object[199]|object[200]	giv[199]|giv[200]	coref|coref	29-49[218_199]|29-49[218_199]
28-25	4015-4022	similar	object[199]|object[200]	giv[199]|giv[200]	_	_
28-26	4023-4025	to	object[200]	giv[200]	_	_
28-27	4026-4030	both	object[200]|person[201]	giv[200]|giv[201]	_	_
28-28	4031-4038	classes	object[200]|person[201]	giv[200]|giv[201]	_	_
28-29	4039-4042	A/B	object[200]|person[201]|event	giv[200]|giv[201]|new	_	_
28-30	4043-4044	,	object[200]	giv[200]	_	_
28-31	4045-4047	as	object[200]	giv[200]	_	_
28-32	4048-4052	well	object[200]	giv[200]	_	_
28-33	4053-4055	as	object[200]	giv[200]	_	_
28-34	4056-4060	with	object[200]	giv[200]	_	_
28-35	4061-4066	lower	object[200]|substance[204]	giv[200]|giv[204]	coref	29-52[219_204]
28-36	4067-4075	activity	object[200]|event|substance[204]	giv[200]|giv|giv[204]	coref	30-13
28-37	4076-4085	compounds	object[200]|substance[204]	giv[200]|giv[204]	_	_
28-38	4086-4087	(	_	_	_	_
28-39	4088-4093	class	abstract[205]	giv[205]	ana	29-1[0_205]
28-40	4094-4095	D	abstract[205]|person	giv[205]|giv	coref	30-24
28-41	4096-4097	)	_	_	_	_
28-42	4098-4099	.	_	_	_	_

#Text=This is probably a result of the practical strategies applied in medicinal chemistry where inactive structures are modified/derivatized to meet or better resemble substructures seen among actives , thus creating this transition from A to D. As concluded from the chemical space observation , this also shows that functionalizing scaffolds from more potent compounds ( class A/B ) might be a feasible initial strategy to find new actives .
29-1	4100-4104	This	abstract	giv	ana	29-45
29-2	4105-4107	is	_	_	_	_
29-3	4108-4116	probably	_	_	_	_
29-4	4117-4118	a	_	_	_	_
29-5	4119-4125	result	_	_	_	_
29-6	4126-4128	of	_	_	_	_
29-7	4129-4132	the	abstract[208]	new[208]	_	_
29-8	4133-4142	practical	abstract[208]	new[208]	_	_
29-9	4143-4153	strategies	abstract[208]	new[208]	_	_
29-10	4154-4161	applied	_	_	_	_
29-11	4162-4164	in	_	_	_	_
29-12	4165-4174	medicinal	abstract[209]	new[209]	_	_
29-13	4175-4184	chemistry	abstract[209]	new[209]	_	_
29-14	4185-4190	where	_	_	_	_
29-15	4191-4199	inactive	abstract[210]	new[210]	_	_
29-16	4200-4210	structures	abstract[210]	new[210]	_	_
29-17	4211-4214	are	_	_	_	_
29-18	4215-4235	modified/derivatized	_	_	_	_
29-19	4236-4238	to	_	_	_	_
29-20	4239-4243	meet	_	_	_	_
29-21	4244-4246	or	_	_	_	_
29-22	4247-4253	better	_	_	_	_
29-23	4254-4262	resemble	_	_	_	_
29-24	4263-4276	substructures	object	new	_	_
29-25	4277-4281	seen	_	_	_	_
29-26	4282-4287	among	_	_	_	_
29-27	4288-4295	actives	animal	new	coref	29-67[223_0]
29-28	4296-4297	,	_	_	_	_
29-29	4298-4302	thus	_	_	_	_
29-30	4303-4311	creating	_	_	_	_
29-31	4312-4316	this	event[213]	new[213]	_	_
29-32	4317-4327	transition	event[213]	new[213]	_	_
29-33	4328-4332	from	event[213]	new[213]	_	_
29-34	4333-4334	A	event[213]|person[214]	new[213]|new[214]	_	_
29-35	4335-4337	to	event[213]|person[214]	new[213]|new[214]	_	_
29-36	4338-4340	D.	event[213]|person[214]	new[213]|new[214]	_	_
29-37	4341-4343	As	_	_	_	_
29-38	4344-4353	concluded	_	_	_	_
29-39	4354-4358	from	_	_	_	_
29-40	4359-4362	the	abstract[216]	giv[216]	_	_
29-41	4363-4371	chemical	abstract[216]	giv[216]	_	_
29-42	4372-4377	space	place|abstract[216]	giv|giv[216]	_	_
29-43	4378-4389	observation	abstract[216]	giv[216]	_	_
29-44	4390-4391	,	_	_	_	_
29-45	4392-4396	this	event	giv	coref	29-56
29-46	4397-4401	also	_	_	_	_
29-47	4402-4407	shows	_	_	_	_
29-48	4408-4412	that	_	_	_	_
29-49	4413-4428	functionalizing	abstract[218]	giv[218]	coref	29-61[222_218]
29-50	4429-4438	scaffolds	abstract[218]	giv[218]	_	_
29-51	4439-4443	from	abstract[218]	giv[218]	_	_
29-52	4444-4448	more	abstract[218]|abstract[219]	giv[218]|giv[219]	appos	29-56[221_219]
29-53	4449-4455	potent	abstract[218]|abstract[219]	giv[218]|giv[219]	_	_
29-54	4456-4465	compounds	abstract[218]|abstract[219]	giv[218]|giv[219]	_	_
29-55	4466-4467	(	_	_	_	_
29-56	4468-4473	class	abstract|abstract[221]	giv|giv[221]	coref|coref	30-22[228_0]|30-22[228_0]
29-57	4474-4477	A/B	abstract[221]	giv[221]	_	_
29-58	4478-4479	)	_	_	_	_
29-59	4480-4485	might	_	_	_	_
29-60	4486-4488	be	_	_	_	_
29-61	4489-4490	a	abstract[222]	giv[222]	coref	30-3[224_222]
29-62	4491-4499	feasible	abstract[222]	giv[222]	_	_
29-63	4500-4507	initial	abstract[222]	giv[222]	_	_
29-64	4508-4516	strategy	abstract[222]	giv[222]	_	_
29-65	4517-4519	to	_	_	_	_
29-66	4520-4524	find	_	_	_	_
29-67	4525-4528	new	animal[223]	giv[223]	_	_
29-68	4529-4536	actives	animal[223]	giv[223]	_	_
29-69	4537-4538	.	_	_	_	_

#Text=However , selected scaffolds should also be sufficiently dissimilar to the lower activity scaffolds , effectively avoiding the right-end tail of the class D ( i. e. , the most similar scaffolds to A , which are still largely inactive ) .
30-1	4539-4546	However	_	_	_	_
30-2	4547-4548	,	_	_	_	_
30-3	4549-4557	selected	object[224]	giv[224]	coref	30-11[226_224]
30-4	4558-4567	scaffolds	object[224]	giv[224]	_	_
30-5	4568-4574	should	_	_	_	_
30-6	4575-4579	also	_	_	_	_
30-7	4580-4582	be	_	_	_	_
30-8	4583-4595	sufficiently	_	_	_	_
30-9	4596-4606	dissimilar	_	_	_	_
30-10	4607-4609	to	_	_	_	_
30-11	4610-4613	the	object[226]	giv[226]	appos	30-29[230_226]
30-12	4614-4619	lower	object[226]	giv[226]	_	_
30-13	4620-4628	activity	abstract|object[226]	giv|giv[226]	_	_
30-14	4629-4638	scaffolds	object[226]	giv[226]	_	_
30-15	4639-4640	,	_	_	_	_
30-16	4641-4652	effectively	_	_	_	_
30-17	4653-4661	avoiding	_	_	_	_
30-18	4662-4665	the	abstract[227]	new[227]	_	_
30-19	4666-4675	right-end	abstract[227]	new[227]	_	_
30-20	4676-4680	tail	abstract[227]	new[227]	_	_
30-21	4681-4683	of	abstract[227]	new[227]	_	_
30-22	4684-4687	the	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
30-23	4688-4693	class	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
30-24	4694-4695	D	abstract[227]|abstract[228]|person	new[227]|giv[228]|giv	_	_
30-25	4696-4697	(	_	_	_	_
30-26	4698-4700	i.	_	_	_	_
30-27	4701-4703	e.	_	_	_	_
30-28	4704-4705	,	_	_	_	_
30-29	4706-4709	the	object[230]	giv[230]	_	_
30-30	4710-4714	most	object[230]	giv[230]	_	_
30-31	4715-4722	similar	object[230]	giv[230]	_	_
30-32	4723-4732	scaffolds	object[230]	giv[230]	_	_
30-33	4733-4735	to	object[230]	giv[230]	_	_
30-34	4736-4737	A	object[230]	giv[230]	_	_
30-35	4738-4739	,	_	_	_	_
30-36	4740-4745	which	_	_	_	_
30-37	4746-4749	are	_	_	_	_
30-38	4750-4755	still	_	_	_	_
30-39	4756-4763	largely	_	_	_	_
30-40	4764-4772	inactive	_	_	_	_
30-41	4773-4774	)	_	_	_	_
30-42	4775-4776	.	_	_	_	_
